S-ClassAbout S-Class
U
UNCYAI Stock Diagnostic Report
Unicycive Therapeutics GAAP EPS of -$0.06 beats by $0.27
Unicycive Therapeutics reported earnings per share (EPS) that exceeded expectations.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$5.0Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support4.71
Near-Term Resistance5.87
02
FUNDAMENTALS
Financial & Fundamental Analysis
GAAP EPS was -$0.06, exceeding the expected figure by $0.27, resulting in a performance surprise; however, there is a lack of guidance to support additional financial momentum or fundamental improvements beyond the earnings announcement.
03
TECHNICAL VIEW
Technical Position & Response Criteria
The current price of $5.00 is positioned between the 20-day low support line and the high resistance line, and there is a possibility of testing lower support due to insufficient trading volume.
Support4.71
Resistance5.87
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
An earnings surprise (EPS beat) occurred, but trading volume is low at 56% of the 20-day average, preventing an immediate influx of trend-based buying in the market.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-08-12)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.